中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (10): 1468-1473.doi: 10.3969/j.issn.2095-4344.2016.10.014

• 肿瘤干细胞 cancer stem cells • 上一篇    下一篇

卵巢癌CD90+肿瘤干细胞的生物学特性

刘智慧1,向志辉2   

  1. 1武汉市妇女儿童医疗保健中心,湖北省武汉市 430016;2华中科技大学同济医学院附属武汉市中心医院,湖北省武汉市 430000
  • 收稿日期:2016-01-25 出版日期:2016-03-04 发布日期:2016-03-04
  • 作者简介:刘智慧,女,1982年生,湖北省武汉市人,汉族,在读硕士,主要从事妇产科研究。

Biological features of CD90+ tumor stem cells in ovarian cancer

Liu Zhi-hui1, Xiang Zhi-hui2   

  1. 1Wuhan Women and Children Medical Care Center, Wuhan 430016, Hubei Province, China; 2the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430000, Hubei Province, China
  • Received:2016-01-25 Online:2016-03-04 Published:2016-03-04
  • About author:Liu Zhi-hui, Studying for master’s degree, Wuhan Women and Children Medical Care Center, Wuhan 430016, Hubei Province, China

摘要:

文章快速阅读:

文题释义:

CD90蛋白:CD90,又称Thy-1,是细胞黏附分子免疫球蛋白超家族的成员。目前在神经细胞、胸腺细胞、成纤维细胞亚群、内皮细胞、肾小球系膜细胞、造血干细胞等表面均有发现。CD90蛋白已被确定在非淋巴组织的多种干细胞中均有不同程度的表达。CD90可以调节细胞-细胞、细胞-细胞质之间的反应,在神经再生和转移、炎症以及纤维化中起重要作用。
肿瘤干细胞:肿瘤中具有自我更新能力并能产生异质性肿瘤细胞的细胞。传统观念认为,肿瘤是由体细胞突变而成,每个肿瘤细胞都可以无限制地生长。但这无法解释肿瘤细胞似乎具有无限的生命力以及并非所有肿瘤细胞都能无限制生长的现象。肿瘤细胞生长、转移和复发的特点与干细胞的基本特性十分相似,因此,有学者提出肿瘤干细胞的理论。这一理论为重新认识肿瘤的起源和本质,以及临床肿瘤治疗提供了新的方向和视觉角度。

 

背景:卵巢癌干细胞学说认为:肿瘤中有一小部分具备自我更新、多向分化的干细胞,属于卵巢癌复发和耐药的根源。相关研究结果显示:CD90能够作为间充质干细胞和其他癌症的干细胞标志物。
目的:探讨卵巢癌CD90+肿瘤细胞的生物学特性。
方法:从卵巢癌患者腹水中分离原代卵巢癌细胞,以流式分选法得到CD90+、CD90-细胞,采用 RT-PCR法检测干细胞相关基因及上皮间质化相关基因表达,采用Transwell小室侵袭实验观察细胞侵袭力,克隆形成实验观察细胞增殖分化能力,悬浮成球实验观察干细胞潜能,动物体内成瘤实验观察成瘤率。
结果与结论:①原代卵巢癌CD90+细胞的干细胞相关基因CD44、CD133、ALDH1表达以及EMT相关基因N-cad、Vimentine表达明显高于CD90-细胞(P < 0.05),EMT相关基因E-cad表达低于CD90-细胞(P < 0.05)。②随着接种细胞数目的增加,CD90+、CD90-细胞的成瘤率升高,CD90+细胞升高更明显。③CD90+细胞穿膜细胞数、细胞克隆数以及悬浮成球数目显著高于CD90-细胞(P < 0.05)。④结果提示CD90+细胞高表达间质属性基因和干细胞相关基因,具备更高的侵袭力、增殖分化能力、体内成瘤能力和干细胞潜能,CD90+细胞分离可能成为卵巢癌干细胞分离的新方法。 

ORCID: 0000-0003-1998-4794 (刘智慧)

关键词: 干细胞, 肿瘤干细胞, 卵巢癌, 原代细胞, CD90+细胞, 生物学特性

Abstract:

BACKGROUND: Thinking from ovarian cancer stem cell theory shows that: in the tumor cells, there are a fraction of stem cells with self-renewing ability and multipotent differentiation, which are the root causes of ovarian cancer recurrence and drug resistance. Studies have shown that CD90 can be used as a surface marker of mesenchymal stem cells and stem cells of other cancers.
OBJECTIVE: To explore the biological features of CD90+ tumor cells from ovarian cancer tissues.
METHODS: Primary ovarian cancer cells were isolated from the abdominal dropsy of ovarian cancer patients to sort CD90+ and CD90- cells using flow cytometry. RT-PCR was used to detect expressions of stem cell-related genes and epithelial to mesenchymal transition-related genes. Cell invasion was observed by Transwell invasion assay, cell proliferation and differentiation observed by clone formation assay, stem cell potential observed by suspension sphere-forming assay, and tumor formation rate observed by in vivo tumorigenicity experiment.
RESULTS AND CONCLUSION: Compared with the CD90- cells, the expressions of CD44, CD133, ALDH1, N-cad and Vimentine were significantly higher in the CD90+ cells (P < 0.05), but the expression of E-cad was significantly decreased in the CD90+ cells (P < 0.05). Tumor formation rates of CD90- and CD90+ cells were increased significantly with the increase of seeded cell number, which was more obvious in CD90+ cells. The number of transmembrane cells, the number of cell clones and the number of suspended spheres were significantly higher in the CD90+ cells than the CD90- cells (P < 0.05). Experimental findings from this study show that CD90+ cells highly express epithelial to mesenchymal transition-related genes and stem cell-related genes, with higher invasion, proliferation and differentiation, in vivo tumorigenicity and potential of stem cells. CD90+ cell separation may be a new method to separate ovarian cancer stem cells.